Table 5.

Comparison of EGFR mutation status among patients with malignant pleural effusions and primary lung adenocarcinomas

Case	Patient characteristic			EGFR mutation status		Response
	Sex	Age (yr)	Smoking	Primary lung adenocarcinoma	LA-MPEs	Target lesions	Pleural effusion
1	F	71	Never	L858R	L858R	PR	CR
2	M	42	Current	Exon 19 del	Exon 19 del	PR	PR
3	M	81	Former	Exon 19 del	Exon 19 del	PR	PR
4	F	59	Never	Exon 19 del	Exon 19 del	PR	PR
5	F	77	Never	Exon 19 del	Exon 19 del	PR	PR
6	M	81	Current	Exon 19 del	Exon 19 del	No	PR
7	F	52	Never	L858R	Exon 19 del/L858R	PR	SD
8	F	46	Never	Exon 19 del	Exon 19 del	No	SD
9	F	66	Never	L858R	L858R	PR	PD
10	M	87	Former	Exon 19 del/L858R	L858R	PR	PD
11	M	82	Former	Exon 19 del/L858R	Exon 19 del	PR	PD
12	M	58	Former	Exon 19 del	Exon 19 del	PR	PD
13	F	68	Never	Exon 19 del	Exon 19 del	SD	PD
14	F	68	Never	Exon 19 del	Exon 19 del	PD	PD
15	M	62	Former	WT	Exon 19 del/L858R	PR	PD
16	F	62	Current	L858R	WT	SD	PR
17	F	72	Never	Exon 19 del	WT	PD	PD
18	M	71	Former	Exon 19 del	WT	SD	SD
19	F	94	Never	L858R	WT	SD	PD
20	M	62	Never	L858R	WT	SD	PD
21	M	71	Former	WT	WT	SD	PD
22	F	81	Never	WT	WT	No	PR
23	M	71	Current	WT	WT	PD	PD

EGFR, epidermal growth factor receptor; LA-MPE, lung adenocarcinoma-associated malignant pleural effusion; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease; WT, wild type.